Role of IL-6 in Mycobacterium avium-associated immune reconstitution inflammatory syndrome

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 676-682

  Barber, Daniel L ^a   Andrade, Bruno B ^a   McBerry, Cortez ^a   Sereti, Irini ^a   Sher, Alan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 6;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MIXED INFECTION; MORTALITY; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; WASTING SYNDROME;

ADULT; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MIDDLE AGED; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 84892704444     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301004     Document Type: Article

References (30)

1. French, M. A. H. 2012. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med. J. Aust. 196: 318-321.
2. Meintjes, G., R. J. Wilkinson, C. Morroni, D. J. Pepper, K. Rebe, M. X. Rangaka, T. Oni, and G. Maartens. 2010. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 2381-2390.
3. Conesa-Botella, A., G. Meintjes, A. K. Coussens, H. van der Plas, R. Goliath, C. Schutz, R. Moreno-Reyes, M. Mehta, A. R. Martineau, R. J. Wilkinson, et al. 2012. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin. Infect. Dis. 55: 1004-1011.
4. Meintjes, G., K. H. Skolimowska, K. A. Wilkinson, K. Matthews, R. Tadokera, A. Conesa-Botella, R. Seldon, M. X. Rangaka, K. Rebe, D. J. Pepper, et al. 2012. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 186: 369-377.
5. Grant, P. M., L. Komarow, M. M. Lederman, S. Pahwa, A. R. Zolopa, J. Andersen, D. M. Asmuth, S. Devaraj, R. B. Pollard, A. Richterman, et al. 2012. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J. Infect. Dis. 206: 1715-1723.
6. Tadokera, R., G. Meintjes, K. H. Skolimowska, K. A. Wilkinson, K. Matthews, R. Seldon, N. N. Chegou, G. Maartens, M. X. Rangaka, K. Rebe, et al. 2011. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. 37: 1248-1259.
7. Elliott, J. H., K. Vohith, S. Saramony, C. Savuth, C. Dara, C. Sarim, S. Huffam, R. Oelrichs, P. Sophea, V. Saphonn, et al. 2009. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis. 200: 1736-1745.
8. Marais, S., G. Meintjes, D. J. Pepper, L. E. Dodd, C. Schutz, Z. Ismail, K. A. Wilkinson, and R. J. Wilkinson. 2013. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin. Infect. Dis. 56: 450-460.
9. + patients developing immune reconstitution inflammatory syndrome. Blood 116: 3818-3827.
10. + T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 119: 3105-3112.
11. + T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur. J. Immunol. 39: 391-403.
12. Bourgarit, A., G. Carcelain, V. Martinez, C. Lascoux, V. Delcey, B. Gicquel, E. Vicaut, P. H. Lagrange, D. Sereni, and B. Autran. 2006. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20: F1-F7.
13. Bourgarit, A., G. Carcelain, A. Samri, C. Parizot, M. Lafaurie, S. Abgrall, V. Delcey, E. Vicaut, D. Sereni, and B. Autran. 2009. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculinspecific CD4 Th1 cells and KIR-negative γδ T cells. J. Immunol. 183: 3915-3923.
14. Haddow, L. J., O. Dibben, M.-Y. S. Moosa, P. Borrow, and P. J. Easterbrook. 2011. Circulating inflammatory biomarkers can predict and characterize tuberculosisassociated immune reconstitution inflammatory syndrome. AIDS 25: 1163-1174.
15. Zaidi, I., K. Peterson, D. Jeffries, H. Whittle, T. de Silva, S. Rowland-Jones, A. Jaye, and B. C. de Jong. 2012. Immune reconstitution inflammatory syndrome and the influence of T regulatory cells: a cohort study in The Gambia. PLoS One 7: e39213.
16. Stone, S. F., P. Price, J. Brochier, and M. A. French. 2001. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J. Infect. Dis. 184: 1073-1077. (Pubitemid 32955127)
17. Boulware, D. R., K. H. Hullsiek, C. E. Puronen, A. Rupert, J. V. Baker, M. A. French, P. R. Bohjanen, R. M. Novak, J. D. Neaton, and I. Sereti. 2011. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 203: 1637-1646.
18. Morlese, J. F., C. M. Orkin, R. Abbas, C. Burton, N. A. Qazi, M. R. Nelson, N. Imami, and B. G. Gazzard. 2003. Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS 17: 1411-1413. (Pubitemid 36819865)
19. Worsley, C. M., M. S. Suchard, W. S. Stevens, A. Van Rie, and D. M. Murdoch. 2010. Multi-analyte profiling of ten cytokines in South African HIV-infected patients with Immune Reconstitution Inflammatory Syndrome (IRIS). AIDS Res. Ther. 7: 36.
20. Price, P., N. Mathiot, R. Krueger, S. Stone, N. M. Keane, and M. A. French. 2001. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J. Clin. Virol. 22: 279-287. (Pubitemid 32846559)
21. Stone, S. F., P. Price, N. M. Keane, R. J. Murray, and M. A. French. 2002. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med. 3: 21-27. (Pubitemid 34189592)
22. Price, P., G. Morahan, D. Huang, E. Stone, K. Y. M. Cheong, A. Castley, M. Rodgers, M. Q. McIntyre, L. J. Abraham, and M. A. French. 2002. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 16: 2043-2047. (Pubitemid 35205268)
23. Barber, D. L., K. D. Mayer-Barber, L. R. V. Antonelli, M. S. Wilson, S. White, P. Caspar, S. Hieny, I. Sereti, and A. Sher. 2010. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116: 3485-3493.
24. Barber, D. L., B. B. Andrade, I. Sereti, and A. Sher. 2012. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat. Rev. Microbiol. 10: 150-156.
25. Tamura, T., H. Ariga, T. Kinashi, S. Uehara, T. Kikuchi, M. Nakada, T. Tokunaga, W. Xu, A. Kariyone, T. Saito, et al. 2004. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model. Int. Immunol. 16: 1691-1699. (Pubitemid 40003857)
26. Appelberg, R. 1994. Protective role of interferon gamma, tumor necrosis factor alpha and interleukin-6 in Mycobacterium tuberculosis and M. avium infections. Immunobiology 191: 520-525. (Pubitemid 24331478)
27. Appelberg, R., A. G. Castro, J. Pedrosa, and P. Minóprio. 1994. Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice. Immunology 82: 361-364. (Pubitemid 24251616)
28. Genovese, M. C., A. Rubbert-Roth, J. S. Smolen, J. Kremer, M. Khraishi, J. Gómez-Reino, A. Sebba, R. Pilson, S. Williams, and R. van Vollenhoven. 2013. Long-term safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J. Rheumatol. 40: 768-780.
29. Fearon, K. C., D. J. Glass, and D. C. Guttridge. 2012. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16: 153-166.
30. Ando, K., F. Takahashi, S. Motojima, K. Nakashima, N. Kaneko, K. Hoshi, and K. Takahashi. 2013. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31: e69-e72.